The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...

Immunovant and Roivant Sciences said Wednesday that their rare disease drug succeeded in a final-phase study, but the duo won't seek regulatory approval for it. Please watch the video at Investors.com ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Roivant (Nasdaq: ROIV) is a ...

The session will feature Pete Salzmann, CEO of Immunovant, alongside Matt Gline, CEO of Roivant. The live webcast can be accessed through the Roivant Investors website and will be available for ...

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related to its initial drug candidate, batoclimab, against autoimmune disorders ...

An antibody treatment from Immunovant and Roivant Sciences significantly reduced symptoms and disease activity in patients with generalized myasthenia gravis, a debilitating autoimmune disease ...